Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
103.92
-2.04 (-1.93%)
Dec 19, 2024, 1:27 PM EST - Market open
Novo Nordisk Revenue
Novo Nordisk had revenue of 71.31B DKK in the quarter ending September 30, 2024, with 21.42% growth. This brings the company's revenue in the last twelve months to 270.58B, up 26.15% year-over-year. In the year 2023, Novo Nordisk had annual revenue of 232.26B with 31.26% growth.
Revenue (ttm)
270.58B DKK
Revenue Growth
+26.15%
P/S Ratio
n/a
Revenue / Employee
4,206,891 DKK
Employees
64,319
Market Cap
479.36B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 393.90B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher | 42.37B |
| Abbott Laboratories | 41.22B |
NVO News
- 1 day ago - Novo Holdings completes $16.5 bln takeover of Catalent - Reuters
- 1 day ago - Novo Holdings Completes Acquisition of Catalent - Business Wire
- 1 day ago - Photys Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Induced Proximity PHICS Technology for Cardiometabolic Diseases - GlobeNewsWire
- 1 day ago - Novo Nordisk's Ozempic faces EU review for potential eye disease connection - Reuters
- 1 day ago - Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition - CNBC
- 3 days ago - Why the investor craze for Ozempic and rival weight-loss drugs may resume next year - Market Watch
- 3 days ago - Novo's Ozempic faces scrutiny over potential link to rare eye disease - Reuters
- 3 days ago - Novo Nordisk A/S - share repurchase programme - GlobeNewsWire